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This manuscript investigates the negative sequelae (in particular, myalgia) of using 
succinylcholine for patients undergoing tracheal intubation, pretreatment strategies to 
minimize or eliminate these untoward effects, and compare their efficacy.  Various 
strategies are commonplace in the clinical setting, and there are a number of research 
studies that discuss the efficacy of individual agents as well as compare them against 
others.  This manuscript explains the anatomy and physiology of neuromuscular 
junctions, muscle contraction, and their relationship with muscle relaxants used in the 
clinical setting. 
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Comparing Pretreatment Modalities for the Prevention of Succinylcholine-Induced 
Fasciculations in Adults Undergoing Endotracheal Intubation 
 
Background/Statement of the Problem 
  Tracheal intubation is a medical procedure that involves inserting a flexible tube 
into a patient’s trachea.  This serves to secure the airway for surgical procedures and to 
facilitate anesthesia drug administration.  Tracheal intubation is accomplished by a multi-
modal approach that includes sedation, analgesia, and muscle relaxation, which produces 
paralysis.  Paralysis is necessary for this procedure due to the reflex mechanisms of the 
laryngeal muscles, which surround the trachea (Nagelhout, 2014).  Two types of muscle 
relaxants are used for intubation: depolarizing and non-depolarizing.  Succinylcholine is a 
depolarizing muscle relaxant that is widely used in anesthesia for this purpose because it 
has many qualities that are recognized as ideal, such as rapid onset, short duration of 
action, a comfortable margin between muscular relaxation and respiratory 
depression/arrest, and a controllable intensity.  These qualities result in a patient who 
needs less sedation and paralysis compared to longer-lasting sedatives and paralytic 
agents.  In many cases, intubation needs to occur very rapidly.  The advantage of 
succinylcholine, noted as far back as the 1950s, is its ability to meet these characteristics 
(Foldes, McNall, & Borrego-Hinojosa, 1952).  Succinylcholine’s ability to relax muscle 
fibers in less than a minute, as well as fast recovery time in three to five minutes becomes 
potentially life-saving in the event of a difficult or failed intubation (Abbas et al., 2009). 
 The mechanism of action of depolarizing muscle relaxants, such as 
succinylcholine, is to mimic the neurotransmitter acetylcholine at the postsynaptic 
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nicotinic receptor.  When two alpha subunits of this receptor are occupied, sodium passes 
through the membrane and depolarizes the cell.  When this happens, an action potential 
occurs, which produces muscle contractions.  Generating muscle contractions in order to 
produce paralysis may seem counter-intuitive; however, succinylcholine produces a 
sustained depolarization of this receptor, which prohibits it from repolarizing.  The 
inability to repolarize then prevents another depolarization of the cell by inactivating 
sodium channels, which prevents further muscle contractions (i.e. paralysis).  Sustained 
muscular contractions are known as fasciculations, which may be viewed as visible, fast 
contractions of muscle fibers.  It is through this mechanism that succinylcholine produces 
several adverse effects, including postoperative myalgia (which can last several days) and 
increased serum potassium (Hochhalter, 1996).  Therefore, minimizing these adverse 
effects is a concern. 
 Some drugs, including non-depolarizing muscle relaxants, have been shown to 
reduce fasciculations, and as a consequence, reduce adverse effects (True & Carter, 
2003).  Non-depolarizers antagonize the receptor, eliminating the incidence of action 
potentials.  This essentially decreases the number of receptors that succinylcholine can 
influence, thus reducing fasciculations.  A variety of other agents (not muscle relaxants) 
work by different mechanisms, but still reveal a decreased incidence of fasciculations, 
such as propofol, magnesium sulfate, lidocaine, and alfentanil (Hochhalter, 1996).  
 Therefore, the purpose of this project is to conduct a systematic review to 
compare pretreatment modalities for the prevention of succinylcholine-induced 
fasciculations in adults undergoing endotracheal intubation, as measured postoperative 
myalgia.  Next, a review of the literature will be presented. 
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Literature Review 
 Databases used in this literature review were PubMed, Cinahl, Google Scholar, 
and Web of Science.  Keywords searched were “succinylcholine” and “fasciculations” in 
the title or abstract.  Additional keywords included “depolarizing muscle relaxant,” 
“nondepolarizing muscle relaxant,” and “myalgia” and were used in combination with 
succinylcholine and fasciculations in order to eliminate articles that did not use 
succinylcholine.  There were no restrictions on dates as to not exclude historical 
literature. 
Neuromuscular Junction Physiology and Receptor Theory 
 Skeletal muscle contraction is mediated by the peripheral nervous system.  The 
site where communication between the sensory and motor neurons occurs is called the 
neuromuscular junction (NMJ).  The NMJ is composed of three elements:  the 
presynaptic sensory nerve, the postsynaptic motor membrane, and the synaptic cleft 
which lies between the two membranes.  In order for communication to take place, an 
action potential must take place.  An action potential is the response of a cell to an 
electrical impulse, which is mediated by the exchange of intracellular and extracellular 
electrolytes, which is known as depolarization.  This occurs when the electrical charge of 
a cell rises above a certain threshold (Omar & Bollu, 2019).  Immediately after 
depolarization occurs, the cell will begin to repolarize which allows it to receive another 
signal after a short refractory period.  When depolarization occurs on the presynaptic 
membrane, the neurotransmitter acetylcholine is released from the presynaptic structure 
of the sensory neuron, crosses the synaptic cleft, and attaches to nicotinic receptors on the 
postsynaptic structure.  Each receptor has five subunits (the specific site of attachment):  
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two alpha (α), and one each of beta (β), delta (δ), and epsilon (ε) subunits.  Acetylcholine 
only attaches to the alpha subunits.  Furthermore, an action potential is possible only 
when both alpha subunits are occupied by acetylcholine (Dani, 2015).  When this 
happens, the receptor undergoes a structural change, allowing sodium into that cell.  This 
produces an action potential in the cells of the motor neuron and eventually stimulates the 
sarcoplasmic reticulum of the muscle to release calcium, which causes muscle 
contraction (Kuo & Ehrlich, 2015).   
 In the synaptic cleft, the enzyme acetylcholinesterase is available in large 
quantities to begin breaking down and recycling acetylcholine; this process begins almost 
immediately.  If this does not happen, muscular contraction would be sustained due to the 
increased availability of acetylcholine.  Therefore, acetylcholinesterase is the body’s 
regulatory mechanism, which allows muscles to return to a resting state (Nagelhout, 
2014). 
Neuromuscular blocking agents 
 Muscle relaxants are medications administered that purposefully induce 
relaxation.  In anesthesia, the muscles are relaxed to the extent that paralysis occurs, 
which is necessary for endotracheal intubation as well as many surgical procedures.  
These medications block skeletal muscle action potentials by various mechanisms.  Each 
drug has a specific profile which includes its mechanism of action, speed of onset, 
duration of action, and potential side effects.  Neuromuscular blocking agents (NMBAs) 
are divided into two classes:  non-depolarizers and depolarizers (Gulenay & Mathai, 
2018). 
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 Non-depolarizing agents.  The mechanism of action of the non-depolarizing 
agents is to competitively block the alpha subunits of the postsynaptic receptor.  This 
inhibits acetylcholine from occupying the site of action (Clar & Liu, 2019).  This 
inhibition essentially inactivates the receptor, which prohibits any further action 
potentials.  As a result, muscle contractions are prohibited for the life of that agent, which 
are determined mostly by metabolism and redistribution.  Metabolism depends on the 
agent:  some are metabolized in the liver, while others are metabolized by plasma 
enzymes.  Redistribution involves the movement of a drug in the body’s circulation, 
which supplies various “compartments.”  These compartments include those with high 
blood flow and those with low blood flow.  The heart, lungs, brain, kidneys, and liver are 
considered high blood flow areas, while muscle, bone, and adipose tissue are examples of 
low blood flow structures.  A drug is essentially terminated when it is redistributed to 
tissue compartments that have lower blood flow levels (such as adipose tissue) since 
there are no receptors for the drug in that tissue (Nagelhout, 2014). 
 Depolarizing agents.  The mechanism of action of depolarizing agents may at 
first seem counterintuitive, since they produce depolarization and an action potential of 
the postsynaptic motor neuron, producing muscle contraction.  The only depolarizing 
agent used in the United States (U.S.) is succinylcholine (Gulenay & Mathai, 2018).  The 
molecular structure of succinylcholine is identical to two molecules of acetylcholine.  
Therefore, succinylcholine easily binds to both alpha subunits on the postsynaptic 
receptor and produces an action potential, generating muscle contraction.  However, 
because succinylcholine is not susceptible to the same enzyme that breaks down 
acetylcholine, it remains attached to the receptor.  This attachment produces a sustained 
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flow of sodium into the cell and therefore a series of muscle contractions, known as 
fasciculations.  By maintaining the electrical charge above the threshold, because of the 
continued influx of sodium, it prohibits the cell from repolarizing.  After a few moments, 
this sustained depolarization eventually causes the receptors to become desensitized.  The 
muscle finally relaxes but because the receptors are still occupied by succinylcholine, 
further depolarization is not possible until the succinylcholine disassociates and is 
metabolized by different enzymes (Nagelhout, 2014). 
Muscle Contraction Physiology 
 A cascade of events takes place when a signal is sent from the brain to a muscle 
group by motor neurons, called a motor unit.  On the presynaptic side of the NMJ, the 
action potential opens calcium channels, and there is an influx of calcium, a positively 
charged electrolyte, into the neuron.  This increased positive charge causes vesicles that 
contain acetylcholine to migrate to the outer membrane and begin the process that ends 
with its rupture, which releases acetylcholine into the synaptic cleft.  Some acetylcholine 
crosses the cleft and attaches to the two alpha subunits of the nicotinic receptor while 
others are almost immediately bound to acetylcholinesterase to begin the regulatory 
process.  On the postsynaptic side, another action potential is triggered when enough 
acetylcholine attaches to their respective receptors, allowing an influx of sodium into that 
cell.  Thousands or millions of cells are clustered together in the matrix outside of the 
sarcoplasmic reticulum (SR).  Action potentials (electrical impulses) are essentially 
generated simultaneously, which causes cells in the SR to release calcium.  It is this 
release of calcium that causes a unified contraction of muscle fibers (Kuo & Ehrlich, 
2015). 
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 The importance of the contraction of skeletal muscles to animal life is obvious:  
without skeletal muscle contractions, one could not walk, talk, eat, or breathe.  Several 
physiologic changes occur with the continued use of muscle groups.  Anyone who has 
been involved in physical exercise (from walking to weight training) knows some of 
these intuitively:  body temperature rises, and one may end up with sore muscles the 
following day.  These are normal and essentially expected results of using muscles in a 
strenuous fashion; however, many changes take place at the cellular level, which in turn 
have the potential to produce a cascade of events that move beyond those rudimentary 
actions necessary to life (Nagelhout, 2014). 
Potential Adverse Effects of Sustained Muscle Contraction 
 When a cell depolarizes, one of the electrolyte exchanges that occurs is between 
sodium and potassium.  As mentioned previously, sodium (the primary extracellular 
positively charged ion) enters the cell when it is depolarized.  At the same time, 
potassium, the primary intracellular positively charged electrolyte, leaves the cell.  
During sustained depolarization, since potassium is unable to reenter the cell, it is 
introduced into the plasma.  Potassium is regulated within tight margins in serum plasma 
by the kidneys (3.5 – 5.0 mmol/L); too little or too much can have devastating effects on 
cardiac function, including death (Nagelhout, 2014).  The sustained contractions by 
succinylcholine can increase plasma potassium up to 0.5 mmol/L (Hager, 2019).  
Nagelhout (2014) suggests possible increases of up to 1.0 mmol/L.  High plasma 
potassium levels over 5.5 mmol/L is considered hyperkalemia, while levels higher than 
6.0 mmol/L can produce serious cardiac events and may require immediate treatment.  A 
modest increase is usually insignificant in terms of clinical practice; however, if a patient 
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has high potassium levels at baseline (e.g. due to kidney disease), this becomes especially 
dangerous.  Other patient populations that are susceptible to adverse effects of 
hyperkalemia are burn and trauma victims and therefore succinylcholine is 
contraindicated in these patients (Hager, 2019). 
 Continued muscular contraction increases the tissue’s oxygen requirements, 
which in turn increases the body’s basal metabolic rate.  This increased metabolism is the 
mechanism by which energy is changed into the form of heat.  The sustained contraction 
of muscles uses more oxygen than is supplied.  Muscle tissue then changes from aerobic 
to anaerobic metabolism, which produces lactic acid, which is converted to lactate and 
hydrogen ions.  It is the lactate that builds up in the muscle tissue that causes pain in 
subsequent days.  Elevated temperature (hyperthermia) and muscle pain (myalgia) are 
also potential adverse effects of succinylcholine-induced fasciculations (Gulenay & 
Mathai, 2018). 
 Pain.  Pain is an incredibly complex concept that involves various categories and 
descriptions.  For example, it may be classified in terms of longevity (chronic vs. acute) 
and/or the underlying source (nociceptive vs. non-nociceptive).  Nociceptive pain 
involves the stimulation of specific nerve endings in specific locations of the body that 
produce a pain response.  Alternately, non-nociceptive pain involves damage to structures 
of the central or peripheral nervous systems.  This type of pain often has no identifiable 
cause.  Additionally, it is multidimensional in the way it is experienced, involving 
sensory and emotional components (Nagelhout, 2014). 
 Several neurotransmitters (NT) and chemicals in the body serve to enhance or 
suppress pain signals.  These include Substance P, bradykinin, prostaglandins, serotonin, 
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and glutamate among several others.  As some form of tissue damage occurs, these 
chemicals and NT stimulate nociceptors and a pain impulse is generated.  This impulse is 
then transmitted from the peripheral nervous system (PNS) to the central nervous system 
(CNS), which includes the spinal cord and brain.  By a complex communication system, 
these pain signals ascend the spinal cord and are finally perceived as pain in various 
locations in the brain.  The brain then sends signals back through the spinal cord to be 
transmitted to the periphery.  At that point, motor, chemical, and/or physiologic responses 
occur.  For example, a motor response includes the removal of a hand from a painful 
stimulus (like a hot stove).  A chemical response includes the release of chemicals that 
influences further pain perceptions.  Finally, physiologic responses include a faster heart 
rate, faster respiration rate, swelling at the site of injury, and other reactions (Nagelhout, 
2014). 
 Pain, including postoperative pain and myalgia (muscle pain) affects various 
populations differently.  Regarding postoperative pain, there is a lower incidence in 
males, those who take part in muscular exercise or activity, and patients at both extremes 
of age (the very old and the very young).  Pain also occurs with increased severity in 
patients who ambulate earlier in the postoperative period.  Additionally, there is a 
constellation of factors that may either mask or exaggerate pain in general, such as 
biologic, cultural, emotional, and social considerations (Nagelhout, 2014). 
 The issue of pain becomes clinically significant because of the relationship 
between patient perceptions of pain, associated stress, and delayed healing time.  Healing 
is a complex continuum with several stages including inflammation, tissue remodeling, 
and hemostasis.  At the proper time, in the proper sequence, and for the proper duration 
  10   
of time, these stages must occur for healing to occur.  Pain is one of many factors that can 
influence wound healing by interfering with this process (Guo & DiPietro, 2010).  
Therefore, the reduction of stimuli that causes pain, including myalgias, should be a 
significant focus in the clinical setting. 
 Myalgia.  The sustained contraction of muscle fibers during succinylcholine 
administration often produces postoperative myalgia, which may be delayed up to the 
fourth postoperative day.  However, the presence or absence of fasciculations is not 
predictive of subsequent myalgia.  Some patients may experience fasciculations but have 
no postoperative myalgia, while others may have no visible fasciculations yet suffer from 
postoperative myalgia (Abbas et al., 2009).  Similar to general pain, myalgia tends to 
affect populations differently.  Some factors include patient age, surgical position, and 
type of surgery.  Additionally, males tend to have fewer complaints of myalgia than 
females (Hochhalter, 1996).  It is unknown if these factors may or may not have any 
connection to the use of succinylcholine.  Therefore, one cannot definitively conclude 
that postoperative myalgia is a consequence of succinylcholine administration as opposed 
to one or more of these other factors. 
 Myalgia occurs due to the activation of nociceptors, which are receptors that are 
specialized to respond to tissue-damaging stimuli.  The tissue damage is then perceived 
subjectively as pain.  Stimuli are generally either mechanical or chemical in origin.  
Tissue trauma is an example of mechanical stimuli, while adenosine triphosphate (ATP), 
protons (H+ ion), and substance P (SP) are examples of chemical stimuli.  Additionally, 
pathophysiological alterations of tissue are accompanied by a decrease in potential 
hydrogen (pH), making the tissue acidic.  An acidic pH level in muscle tissue is a major 
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factor that leads to muscular pain (Mense, 2008).  In this context, chemical activation is 
the factor to be considered.  Specifically, muscular exercise in the absence of oxygen 
produces lactate as a byproduct.  Lactate has been implicated as a contributing factor in 
pain because it acts on muscular innervation of sensory neurons (Ishii & Nishida, 2014). 
 Free radicals.  An additional byproduct of muscle contractions (and subsequent 
metabolism and cellular function) are free radicals (FR), which can be both beneficial and 
toxic to the body.  The body produces endogenous antioxidants, but at times the 
production of FR exceeds the capabilities of the body’s natural FR “scavengers.”  When 
FR accumulate in the body, a process called oxidative damage occurs.  This refers to 
damage done to a wide array of biomolecules in an indiscriminate and arbitrary manner, 
which then contributes to pain.  Simioni et al. (2017) demonstrated that a relationship 
exists between pain and oxidative stress. Murphy, Myers, Davies, Webster, and Jones 
(1992) note that FR in some way contribute to tissue injury, resulting in many acute 
conditions.  Free radicals have been suggested as causing postoperative myalgia.  
Recently, antioxidants have been investigated as having a potential pain-relieving 
mechanism.  Propofol is one such FR scavenger, and both single-dose and continuous 
intravenous infusions have been effective in preventing postoperative myalgia connected 
with succinylcholine administration (Kararmaz, Kaya, Turhanoglu, & Ozyilmaz, 2003).  
Since pain is a complex concept with varying pathways in the body, it makes sense that a 
diversity of agents (not simply non-depolarizing muscle relaxants), are being used in the 
prevention of myalgias associated with succinylcholine. 
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Measuring Fasciculations and Pain 
 Measuring Fasciculations.  Visible signs and symptoms of many disease 
processes can be subjective, and muscle fasciculations are no different.  In a study done 
by Abbas et al. (2009), fasciculations were measured using a four-point scale from a prior 
study from 1987.  The authors used a four-point numeric tool that scored fasciculations 
from 00 (no fasciculations) to 03 (severe fasciculations).  Mild fasciculations were scored 
as 01, while 02 indicated moderate fasciculations.  However, even though the difference 
between the absence and presence of fasciculations is essentially binary, the difference 
between large muscle twitches and major limb movements may be subjective depending 
on the clinician.  One may interpret major muscle movement as limb movement, in part 
because limbs often contain major muscle groups.  Additionally, if a patient were in a 
supine position, an anesthesia provider could not visibly observe fasciculations of back 
muscles.  A study by Khan, Siddiqi, Anjum, and Hamza (2017) used a similar four-tiered 
0-3 scale.  Virtually every study that measures fasciculations uses a four-tiered system as 
described above; the major differences are the specific descriptions of the tiers. 
 Measuring Pain.  At baseline, pain scores are subjective in nature.  Pain 
perception varies in patients with functional abilities or disabilities.  Other factors such as 
personal motivation, social supports, cultural, and psychological factors also have an 
effect on pain perception.  The continuum of healthcare has brought us to the current use 
of a 0-10 pain scale.  While this can be very helpful, it has drawbacks due to the 
subjective nature of pain and varying levels of sensitivity and tolerance (Krebs, Carey, & 
Weinberger, 2007).  Abbas et al. (2009) cite a 1962 study which measures pain as it 
relates to functional disability.  This measurement tool was also a four-point numeric 
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scale ranging from 00 to 03; 00 indicated no pain, while 03 indicated pain that involved 
more than one site and included functional disability.  Khan et al. (2017) also used a 0 –3 
pain scale.  The authors not only described levels 1 –3 as mild, moderate, and severe, 
they also included the relative necessity of treatment (e.g. level 1 required no treatment, 
level 2 required treatment, and level 3 required additional treatment). 
 Pretreatment Modalities 
 Over the decades, clinicians have been experimenting with a variety of ways to 
attenuate succinylcholine-induced fasciculations.  This includes drugs from several drug 
classes, which work by various mechanisms of action, and include opioids, anti-
epileptics, non-steroidal anti-inflammatory agents, gamma aminobutyric acid (GABA) 
agonists, and others (Khan et al., 2017). 
 Non-depolarizing muscle relaxants.  Because of the mechanism of action of this 
drug class described above, there are fewer receptors available for succinylcholine to 
occupy.  This produces action potentials that are not as intense or sustained as they would 
otherwise be if succinylcholine had full access to all receptors.  For this reason, this drug 
class has been highly popular as regards a pretreatment strategy.  It has also been 
frequently studied and shown to be efficacious for this purpose. 
 GABA agonists.  Propofol, gabapentin, and pregabalin are drugs that act on the 
receptor that deals with the neurotransmitter GABA, which is the body’s main inhibitory 
neurotransmitter.  As an inhibitory neurotransmitter, it blocks particular brain signals, 
which tends to decrease activity in the nervous system.  Since fasciculations are a 
function of the nervous system, inhibiting these signals has been found to block 
fasciculations to some degree.  Gabapentin and pregabalin in particular potentiate GABA 
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as well as inhibit the release of calcium ions inside neurons and muscle cells (Khan et al., 
2017). 
 Magnesium sulphate.  Magnesium sulphate’s exact functions are controversial, 
but it has been shown to minimize two undesirable facets of intubation.  First, as an 
adrenergic antagonist, it blocks catecholamine release during laryngoscopy, including 
raised heart rate and blood pressure.  Second, it has been shown to decrease 
fasciculations.  The authors of one study state that it controls the increase of potassium 
concentration, thereby attenuating muscular action potentials (Ahsan et al., 2016).  
However, Sakuraba et al. (2006) state that while it does decrease fasciculations, it has no 
effect on potassium concentration.  Therefore, while it has efficacy in reducing 
fasciculations, its exact mechanism remains under debate. 
 Opioids.  Opioids, especially remifentanil, have been used in both the induction 
and maintenance phases of anesthesia for decades.  Like magnesium sulphate, they blunt 
the sympathetic response to laryngoscopy.  They also have been shown to reduce the 
intensity of succinylcholine-induced fasciculations, although the mechanism by which 
this occurs remains unexplained (Yun et al., 2010). 
 Next, the theoretical framework will be discussed. 
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Theoretical Framework 
 Random controlled trials (RTCs) are individual snapshots of the overall portrait of 
a particular topic.  Each trial, regardless of sample size, contributes information to the 
larger body of literature.  Dozens or hundreds of trials are conducted in various 
institutions, cities, and countries around the world.  An analysis of related studies that 
compare results is able to greatly enhance the generalizability of the findings, thus 
making an application in the clinical setting more likely.  The collection and distillation 
of random controlled trials is a necessary step in the research process.  Systematic 
reviews and meta-analyses are tools that enable researchers to synthesize data and 
attempt to interpret findings in a way that furthers the scope and enhances the knowledge 
base of a particular area of research.  Additionally, systematic reviews may assist in 
assessing the quality of studies in terms of methods and processes (Liberati et al., 2009). 
 Systematic reviews are facilitated by frameworks such as the Preferred Reporting 
Items for Systematic review and Meta-Analyses (PRISMA).  Using this framework 
enables one to compile and examine the strengths and weaknesses of each RCT, thus 
revealing a wide-angle viewpoint instead of a close-up, focused glimpse of a topic.  
PRISMA is an accepted protocol for systematic reviews largely because the flow and 
results depend heavily on both the scope and quality of the studies included.  Therefore, 
the PRISMA Statement (Figure 1) was developed to guide the authors of systematic 
reviews.  The Statement is a checklist consisting of twenty-seven items as well as a 
flowchart (Figure 2) to follow step by step.  In using these, PRISMA helps to govern the 
analysis of RCTs, thus maintaining consistency among systematic reviews and meta-
analyses (Liberati et al., 2009).  
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TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data 
sources; study eligibility criteria, participants, and interventions; study appraisal and 
synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
3 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  5 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
6 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), 
and, if available, provide registration information including registration number.  
19-22 
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Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics 
(e.g., years considered, language, publication status) used as criteria for eligibility, giving 
rationale.  
23 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
23 
Search  8 Present full electronic search strategy for at least one database, including any limits used, 
such that it could be repeated.  
23-24 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic 




10 Describe method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators.  
24-25 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and 
any assumptions and simplifications made.  
24 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how this 
information is to be used in any data synthesis.  
37 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  n/a 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis.  
24 
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Section/topic  # Checklist item  
Reported 
on page #  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies).  
37 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified.  
27 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram.  
24 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, 
PICOS, follow-up period) and provide the citations.  
28-34 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment 
(see item 12).  
37 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple 
summary data for each intervention group (b) effect estimates and confidence intervals, 
ideally with a forest plot.  
33-34 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
34 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  37 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression [see Item 16]).  
34 
  19   
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy 
makers).  
34-36 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  
36-37 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research.  
38 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of 
data); role of funders for the systematic review.  
n/a 
 
Figure 1. Completed PRISMA checklist 





















Figure 2. Completed PRISMA flowchart 
 Next the methods will be discussed.  
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(n = 16) 
Full-text articles 
excluded (n=12), with 
reasons: 
Not in English (n=1) 
Not an RCT (n=3) 
Pediatric population 
(n=1) 
Pretreatment agent not 
assessed (n=2) 
Post-op myalgia not 
assessed (n=3) 
Fasciculations not focus 
of study (n=2) 
Studies included in qualitative 
synthesis (n = 4) 
Studies included in 
quantitative synthesis (meta-
analysis) (n = 4) 
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Methods 
Purpose 
 The purpose of this project was to conduct a systematic review to compare 
pretreatment modalities for the prevention of succinylcholine-induced fasciculations in 
adults undergoing endotracheal intubation.  The research question that will be examined 
is:  Of the known and available pretreatment modalities for the prevention of 
succinylcholine-induced fasciculations, which modality has the greatest efficacy as 
measured by postoperative myalgia? 
Inclusion and exclusion criteria 
 Inclusion criteria were:  (1) randomized controlled trials from 2010 to 2020, (2) in 
adult patients aged 18 and older, (3) with a primary focus on succinylcholine-induced 
fasciculations, (4) American Society of Anesthesiologists (ASA) classes I and II, (5) and 
written in English.  Pediatric studies were excluded due to significant physiological 
differences in organ maturation, drug metabolism, medication dosing, and drug response 
(Nagelhout, 2014).  The ASA classifies patients according to physical status with regards 
to the presence & severity of systemic disease (e.g. hypertension, diabetes, heart failure), 
using class I through V.  Class III and above indicate patients with severe systemic 
disturbances that either limit activity or are life-threatening, or those for whom surgery is 
a resuscitative effort, with a minimal chance of survival (Nagelhout, 2014).  Therefore, 
class III and above were excluded due to these confounding factors. 
Search strategy 
 PubMed and Web of Science were searched for randomized controlled trials using 
the following search criteria:  (1) randomized clinical trials, (2) “succinylcholine” in title 
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or abstract, (3) “fasciculation*” in title or abstract, and (4) date range 2010 to 2020.  
Fasciculation was searched using the wildcard “*” to capture both “fasciculation” and 
“fasciculations.” The PubMed search initially yielded eleven studies (n=11) and the Web 
of Science search yielded nine (n=9), for a total of twenty studies.  Four were rejected as 
duplicates, two were rejected because the study was not examining a pretreatment agent, 
two were rejected because fasciculations were not the focus of the study, one was 
rejected because English was not the primary language, one was rejected because 
pediatric patients were included, three were rejected because the studies did not assess 
postoperative myalgia, and three were rejected because the studies were not randomized 
controlled trials.  This yielded a total of four studies that were included in this systematic 
review.  
Data collection and synthesis approach 
 The results of each RCT were placed in two tables.  Table 1 displays data that was 
collected from each RCT and includes the author, sample size, dose of succinylcholine, 
pretreatment agent, and the percentage of patients with fasciculations at each level of a 4-
point scale.  Table 2 will display data that reflects the author, pretreatment agent utilized, 
the time-frame myalgia was measured in (hours postoperative), as well as incidence and 
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Critical appraisal instruments 
 The Critical Appraisal Skills Programme (CASP) will be used to critically 
appraise each RCT (Figure 3).  The Critical Appraisal Skills Programme contains eleven 
questions that are applied to each study.  The answers to these questions are analyzed to 
determine the validity, relevance, trustworthiness, and usefulness of studies.  Within the 
first two questions, it can be determined if that particular study is valid enough to 
continue the appraisal (Critical Appraisal Skills Programme [CASP], 2017).  By critically 
appraising each RCT, conclusions and results are anticipated to be sufficient to make 
informed conclusions and recommend further research in this area. 
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Cross Analysis 
 After critically appraising each randomized control trial utilizing CASP, the 
studies will be evaluated to compare similarities and differences across the studies.  
Fasciculations and postoperative myalgia will be assessed according to a 24-hour 
timeframe, which all studies reviewed used.  These will be divided into two columns:  
none to mild with a score of 0 or 1, or moderate to severe with a score of 2 or 3 (table 3). 




score of 0 or 1 
Fasciculation 
score of 2 or 
3 
Myalgia score 
of 0-1 at 24 
hrs 
Myalgia score 
of 2-3 at 24 
hrs 
      
 
Dissemination of Findings 
 Ideally, findings of a systematic review should influence clinical practice if the 
findings are significant.  With this in view, the optimal audience would be anesthesia 
providers.  At present, a major paper and poster presentation will be used for initial 
dissemination. 
 Next, the results of this systematic review will be presented. 
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Results 
 The completed PRISMA flow diagram in the theoretical framework section 
(Figure 2) demonstrates the process used which yielded the final four studies that were 
reviewed, as described in the search strategy of the methods section.  The results from 
each of these studies were placed in Tables 1 and 2.  Cross analysis was performed and 
the results were placed in Table 3.  All of these appear at the end of the results section.  
Additionally, a CASP table was completed for each study (Appendix A). 
 Yun et al. (2010) evaluated the use of remifentanil as a pretreatment modality.  In 
this double-blind study, two equal groups (n=20) of adult patients were analyzed under 
controlled intubating conditions.  One group received remifentanil while the other 
received normal saline.  Both subjective and objective means were utilized to determine 
presence and severity of fasciculations.  The intensity and duration of fasciculations were 
noted and recorded following administration of succinylcholine.  90% of the control 
group experienced fasciculations while 85% of the intervention group experienced 
fasciculations.  Further, the duration of fasciculations in the intervention group was 41.6 
seconds vs. 59.6 seconds in the control group.  Myalgia was recorded twenty-four hours 
after the time of induction.  Objective data included the use of electromyography 
whereby muscle action potentials are measured using electrodes.  Recordings of the 
amplitude of the action potentials are able to quantify the degree of fasciculations.  
Additionally, serum potassium levels were analyzed five minutes after succinylcholine 
administration and creatine kinase (CK) levels were analyzed twenty-four hours after 
induction time.  Both potassium and CK give an indication of muscle activity and cellular 
breakdown.  The results showed a decrease in the intensity of fasciculations in the 
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remifentanil group, but similarities were found in both incidence and duration of 
fasciculations between the groups.  With respect to myalgia, there was no statistically 
significant difference between the two groups:  only one patient experienced mild 
myalgia in the remifentanil group, and only two experienced mild myalgia in the control 
group.  Moderate and severe myalgia were absent in both groups.  The authors concluded 
that remifentanil was able to attenuate the intensity of fasciculations but produced no 
notable effect on postoperative myalgia.  The authors suggested that dosing regimens 
could be studied and potentially optimized for this use. 
 Khan, Siddiqi, Anjum, & Hamza (2017) performed a randomized controlled study 
using pregabalin, an anti-epileptic drug that acts on the neurotransmitter GABA.  Seventy 
patients were divided into two equal groups.  The control group received a placebo pill 
while the intervention group were administered 150 mg of pregabalin, both two hours 
before induction of anesthesia and administration of succinylcholine.  Fasciculation 
incidence and intensity was measured using a four-point scale by a blinded resident 
doctor.  Additionally, 24 hours after the surgery, myalgia was assessed using a similar 
four-point scale.  The results demonstrated a significant difference between the incidence 
and severity of myalgia in the first 24 hours of the postoperative period (p=0.000).  
However, the incidence of fasciculations was not statistically significant between the two 
groups (p=0.096), although the severity seemed to be decreased in the intervention group.  
Further, all patients who received pregabalin tolerated it well, and none experienced any 
significant side effects of the drug (e.g. somnolence).  Limitations of this study include 
the fact that it was a single type of surgical procedure (laparoscopic cholecystectomy) at a 
single site.  However, a wider scope of surgical procedures will most likely not influence 
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generalizability to any significant degree since the only issue being assessed is 
fasciculations associated with the induction/intubation period.  Since postoperative 
myalgia is being assessed, one issue may be that other procedures have a higher degree of 
postoperative pain associated with them.  This may influence a patient’s assessment of 
myalgia that is strictly due to fasciculations. 
 Pandey, Tripathi, Joshi, Karna, Singh, and Singh (2012) studied gabapentin, 
another anti-epileptic drug similar to pregabalin.  Seventy patients participated in this 
study.  The intervention group (n=35) received an oral dose (600 mg) of gabapentin two 
hours prior to surgery while the control group (n=35) received a placebo (also 
administered orally).  1.5 mg/kg of succinylcholine was used in both groups, and all other 
adjunct medications (fentanyl, thiopentone, and maintenance drugs) were the same.  The 
results showed a significant decrease in the postoperative incidence and severity of 
myalgia (p<0.05) between the groups.  In the control group, twenty experienced myalgia 
in the first 24 hours postoperative.  This was contrasted with only eleven in the 
intervention group experiencing myalgia in the same time period.  There was no 
statistically significant difference on the incidence or severity of fasciculations between 
the groups.  However, since myalgia involves the patient’s perception of pain and/or 
discomfort, it is a more significant measure of the efficacy of a pretreatment drug as 
compared to the measure of the incidence and/or severity of fasciculations, which the 
patient is unaware of.  An additional discovery in this study was that the use of 
gabapentin decreased the need for intra-operative pain medications, measured by the 
administration of fentanyl.  As with Khan et al., this study assessed only laparoscopic 
cholecystectomy procedures at a single site. 
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 Vyankatesh, Kiran, and Satish (2016) performed a study that compared two non-
depolarizing muscle relaxant drugs against both one another as well as a control group.  
One hundred fifty patients were divided into three equal groups of fifty.  Group NS 
(control group) received 2 mL of normal saline, group V received 0.1 mg/kg of 
vecuronium, and group R received 0.06 mg/kg of rocuronium for pretreatment. ASA I & 
II patients of both genders with a mean age between 35.5 and 37.3 were included in this 
study.  The results showed that the group that received rocuronium had the largest 
number of patients with fasciculations graded as 0 or 1 (100%), followed by the group 
that received vecuronium (88%).  The control group had just 28% with a 0 or 1 grade.  
The inverse was true regarding fasciculations with a grade of 2 or 3:  the control group 
(group NS) had 72% at that severity level, group V had 24%, while group R had 0%.  
Concerning postoperative myalgia at 24 hours out, the results essentially followed those 
regarding fasciculations, as displayed in table 3.  Group R had the highest percentage in 
the 0 category, followed by group V and then by group NS.  As for scores 1, 2, and 3 
(mild, moderate, and severe, respectively) on the four-point myalgia scale, group NS had 
the most of all three groups at each level, followed by group V, with group R showing the 
least percentage of postoperative myalgia of all groups.  Of note, this was the only study 
in this review that assessed myalgia at a postoperative timeframe of greater than 24 
hours.  The results basically mirrored those of postoperative day 1.  However (and 
interestingly), the percentages of all three groups at level 0 (no myalgia) decreased, while 
those of the other levels of myalgia increased with only a few exceptions:  at no 
assessment was there level 3 myalgia in group V, and at no assessment were there levels 
2 or 3 in group R. 
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 One error was noted in the fasciculation-scoring table of this study for the group 
that received vecuronium:  the amount of participants added up to 56 instead of 50; 
therefore, the percentages also ended up high (112%).  This was the only table noted to 
have this error; all others correctly added up to a total of 50 in the group.  These incorrect 
results are still included in this systematic review as they appear in the study; however, 
the reader should be aware that the results are not completely accurate as regards 
fasciculations.  Since the myalgia scores are the main end focus of this review, the study 
in its entirety was not excluded since the data from the myalgia table added up correctly. 
 This study when compared to the other three displayed more tables showing a 
greater breadth of clinically relevant outcomes.  These included urine myoglobin, serum 
CPK levels, and serum potassium levels, all of which are relevant sequelae of 
succinylcholine administration. 

















Yun et al., 
2010 
n=40 1 Remifentanil 0 = 15% 
1 = 65% 
2 = 20% 
3 = 0% 
0 = 10% 
1 = 5% 
2 = 60% 
3 = 25% 
Khan et al., 
2017 
n=70 1.5 Pregabalin 0 = 8.5% 
1 = 48.5% 
2 = 40 % 
3 = 3% 
0 = 8.5% 
1 = 28.5% 
2 = 43% 






n=70 1.5 Gabapentin 0 = 14% 
1 = 46% 
2 = 34% 
3 = 6% 
0 = 17% 
1 = 23% 
2 = 49% 
3 = 11% 














* results add 
up to 112% as 
noted 
0 = 76% 
1 = 24% 
2 = 0% 
3 = 0% 
 
0 = 52% 
1 = 36% 
2 = 12% 
3 = 12% 
 
0 = 0% 
1 = 28% 
2 = 60% 
3 = 12% 
Table 2 – Data Collection Tool 2 – RESULTS 
Author Pretreatment 
agent 




Myalgia at 24 
hrs postoperative 
(control group) 






0 = 95% 
1 = 5% 
2 = 0% 
3 = 0% 
0 = 90% 
1= 10% 
2 = 0% 
3 = 0% 





0 = 31.4% 
1 = 54.3% 
2 = 14.3% 
3 = 0% 
0 = 6% 
1= 29% 
2 = 51% 







0 = 57% 
1 = 31.5% 
2 = 11.5% 
3 = 0% 
0 = 31% 
1= 40% 
2 = 29% 











0 = 88% 
1 = 12% 
2 = 0% 
3 = 0% 
 
0 = 72% 
1 = 20% 
2 = 8% 
3 = 0% 
0 = 16% 
1= 52% 
2 = 24% 
3 = 8% 
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score of 0 or 
1 
Fasciculation 
score of 2 or 
3 
Myalgia 
score of 0-1 
at 24 hrs 
Myalgia 
score of 2-3 
at 24 hrs 
Yun et al., 
2010 
Remifentanil 80% 20% 100% 0% 
Khan et al., 
2017 
Pregabalin 57% 43% 85.7% 7.1% 
Pandey et 
al., 2012 









results add up 
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Summary and Conclusions 
 Succinylcholine is a popular muscle relaxant useful in a number of tracheal 
intubation situations, particularly rapid sequence intubation (RSI).  Its rapid onset and 
metabolism by innate enzymes make it an ideal choice for this purpose, especially when 
coupled with shorter procedures which do not require longer lengths of time of muscle 
relaxation.  However, its side effect profile includes fasciculations, which quite often 
produce myalgias in the immediate postoperative period (Yun et al., 2010).  Because of 
this, clinicians have experimented with a variety of other agents to use as a pretreatment 
adjunct to succinylcholine in an attempt to attenuate or eliminate fasciculations and 
myalgias.  Many of these other agents, because of their mechanisms of action, have been 
shown to be beneficial for this purpose, with varying degrees of success. 
 The purpose of this systematic review was to identify agents that reduce or 
eliminate fasciculations as evidenced by an absence of postoperative myalgias, compare 
them using a variety of tools, and attempt to identify a single agent that is superior to the 
others. The literature review focused on cell receptor theory, the mechanism of muscle 
contraction, the mechanism of action of muscle relaxant drugs used in anesthesia, and 
pain.  The theoretical framework utilized both PRISMA and CASP, which are considered 
the gold standard for systematic reviews.  The former includes a checklist and flowchart 
with which to organize, include, or exclude studies depending on their applicability, 
while with the latter one is able to judge the integrity, validity, and rigor of a study or 
experiment.  Using these in tandem, one may form certain conclusions and identify 
correlations that may be useful in answering the research question.  This analysis was 
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performed on the four studies that met criteria for inclusion.  Cross analysis was then 
performed on the data that was collected, which establishes certain findings. 
 To summarize, the results of the cross analysis (Table 3) demonstrate that every 
agent used to reduce fasciculations was efficacious, to varying degrees.  To be clear, even 
though both rocuronium and remifentanil had myalgia scores of 100% in the 0 or 1 score 
levels and 0% in the 2 or 3 score levels, there is a vast difference between the two.  The 
difference between the rocuronium and control groups was significant, even though a p 
value was not specifically given.   In the remifentanil study, this percentage reflected only 
one patient who experienced myalgia, while there were only two in the control group; 
therefore, this is not statistically significant.  However, it is interesting to note that in the 
remifentanil study (Yun et al., 2010), a total of only 3 participants reported myalgia of 
any severity, which is not even 1% of the whole.  That is a significantly lower percentage 
than any of the other studies.  Perhaps there is a correlation between the dose of 
succinylcholine as compared to the other studies; in this study, only 1 mg/kg was used, 
while the other three studies used 1.5 mg/kg.  Possibly a reduced dose of succinylcholine 
would produce acceptable intubating conditions while at the same time mitigating its own 
postoperative myalgia.  Yun et al. did not note any difficult intubating conditions as a 
result of the lower dose of succinylcholine.  Additionally, this was the only study that 
noted the duration in seconds of the fasciculations.  It would be interesting in future 
research to compare incidence, severity, and duration of fasciculations as those factors 
relate to postoperative myalgia. 
 This synthesis and evaluation points to the findings of this systematic review.  
The research question asked which agent was the most efficacious in eliminating or 
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reducing succinylcholine-induced fasciculations as measured by postoperative myalgia.  
To this end, it seems that rocuronium, a nondepolarizing muscle relaxant, has the greatest 
efficacy in the elimination and/or reduction of both the frequency and severity of both 
fasciculations and myalgia as compared to a control group.  However, as noted above, a 
secondary finding seems to suggest that a lower dose of succinylcholine (with or without 
a pretreatment agent,) may be used for intubation, and reduce fasciculations.  This dosing 
adjustment may in turn diminish postoperative myalgia. 
 There were a number of limitations identified while performing this systematic 
review.  Only the most recent studies were included (2010-present).  While this focuses 
on current modalities and clinical practice, it excludes other agents that perhaps have not 
been studied recently but that are still in use clinically, or agents that are used elsewhere 
globally that are more accessible and less expensive than their first-world counterparts.  
In every study, only patients classified as ASA I or II were included, which could limit 
generalizability.  Additionally, only certain procedures were reflected in these studies.  
Two of these were laparoscopic cholecystectomy, one (Yun et al., 2010) included only 
elective otolaryngological surgery specifically because it carries a minimal risk of serum 
CK increases, and the last did not disclose the type(s) of procedure(s).  RSI is used in 
many emergent, trauma, and difficult airway cases; it is difficult to know if there are 
confounding factors associated with these types of procedures that do not exist in a 
relatively controlled environment.  Additionally, patients with known conditions such as 
neuromuscular diseases or morbid obesity, and those at the extremes of age were 
excluded (Yun et al., 2010).  Some of these conditions contraindicate the use of 
succinylcholine (e.g. certain neuromuscular diseases), but others do not; however, 
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without studying a wider population, including special populations, results may not be 
generalizable. 
 Risk of bias is always present in any study; however it can be minimized by being 
transparent as regards the methods and reporting of the results.  These four studies were 
blinded, randomized controlled trials, with methods clearly communicated and therefore 
easily duplicated.  Therefore, the risk of bias seems quite negligible.  However, the 
subjectivity as regards the reporting of both fasciculations and postoperative myalgia 
could contain varying degrees of risk of bias.  Since pain contains physical, emotional, 
and psychological elements, the reporting of postoperative pain may be laden with bias:  
some patients may feel free to report (with or without exaggeration), while others may be 
relatively stoic in their approach to pain and reporting it. 
  
  37   
Recommendations and Implications for Advanced Nursing Practice 
 The ultimate goal for research is to impact clinical practice.  It is obvious that 
fasciculations associated with the administration of succinylcholine very often produce 
myalgia for the patient in the postoperative period; this has been a clinical concern for 
decades.  This impacts the patient’s perception of the healthcare system in general, which 
flows down to individual disciplines within the healthcare system, including anesthesia.  
Therefore, minimizing or eliminating this unpleasant side effect has been, and should 
continue to be, a focus for APN anesthesia providers.  Various drugs that can be used for 
this purpose are readily available and should be used if there are no contraindications.  
This would serve to increase the quality of our practice, and in a broad sense be a way 
that we advocate for our patients’ postoperative comfort. 
 As noted above with the different dosing of succinylcholine, future research could 
focus on using smaller doses of succinylcholine in conjunction with a pretreatment agent 
in order to reduce or eliminate myalgia.  Centrally located nerves and muscles (e.g. face, 
throat) are affected before peripheral nerves and muscles (arms, hands, legs); therefore, 
could an alternate dosing strategy be developed to produce enough paralysis for 
intubation, without the need to affect 100% of every peripheral receptor? 
 Results shown here, as well as future research, can be promulgated on a broader 
scale.  This could include various publications and conference presentations.  Ultimately, 
it is up to each individual provider of anesthesia to be an active and critical consumer of 
research information in whatever form it takes, and seek to implement new, clinically 
relevant data into practice.  Additionally, policy development for the APN is an important 
facet of clinical practice.  This does not always need to be at a national or state level; we 
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have the ability to develop protocols and policies at individual institutions regarding more 
comprehensive patient education before a procedure (i.e. possible symptoms they may 
experience postoperatively) as well as patient follow-up in the postoperative period.  This 
may go a long way to build trust between patients and health care providers. 
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Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
 
Study 1: Yun, M.J., Kim, Y.H., Go, Y.K., Shin, J.E., Ryu, C.G., Kim, W., Paik, N.J., 
Han, M.K., Do, S.H., & Jung, W.S. (2010). Remifentanil attenuates muscle fasciculations 
by succinylcholine. Yonsei Medical Journal, 51(4). 
A) Are the results of the trial valid? Yes Can’t 
tell 
No 
1. Did the trial address a clearly focused issue? x   
2. Was the assignment of patients to treatments randomized? x   
3. Were all of the patients who entered the trial properly 
accounted for at its conclusion? 
x   
4. Were patients, health workers, and study personnel “blind” to 
treatment? 
x   
5. Were the groups similar at the start of the trial? x   
6. Aside from the experimental intervention, were the groups 
treated equally? 
x   
B) What are the results?  
7. How large was the treatment effect? 40 otolaryngological 
patients. 
8. How precise was the estimate of the treatment effect? No statistically 
significant decrease in 
myalgia. 
C) Will the results help locally?  
9. Can the results be applied in your context? (or to the local 
population) 
x   
10. Were all clinically important outcomes considered?   x 
11. Are the benefits worth the harms and costs? x   
 
 
  44   
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
 
Study 2: Khan, M.A., Siddiqi, K.J., Anjum, K.M., & Hamza, A. (2017). A randomized 
controlled study on prevention of succinylcholine induced fasciculation and myalgia by 
pretreatment with pregabalin in patients undergoing laparoscopic cholecystectomy. 
Anaesthesia, Pain & Intensive Care, 21(4). 
A) Are the results of the trial valid? Yes Can’t 
tell 
No 
1. Did the trial address a clearly focused issue? x   
2. Was the assignment of patients to treatments randomized? x   
3. Were all of the patients who entered the trial properly 
accounted for at its conclusion? 
x   
4. Were patients, health workers, and study personnel “blind” to 
treatment? 
x   
5. Were the groups similar at the start of the trial? x   
6. Aside from the experimental intervention, were the groups 
treated equally? 
x   
B) What are the results?  
7. How large was the treatment effect? 70 laparoscopic 
cholecystectomy 
patients. 
8. How precise was the estimate of the treatment effect? Decrease of myalgia 
was statistically 
significant. 
C) Will the results help locally?  
9. Can the results be applied in your context? (or to the local 
population) 
x   
10. Were all clinically important outcomes considered?   x 




  45   
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Study 3:  Pandey, C.K., Tripathi, M., Joshi, G., Karna, S.T., Singh, N., & Singh, P.K. 
(2012). Prophylactic use of gabapentin for prevention of succinylcholine-induced 
fasciculation and myalgia: a randomized, double-blinded, placebo-controlled study. 
Journal of Postgraduate Medicine, 58(1). 19-22. 
A) Are the results of the trial valid? Yes Can’t 
tell 
No 
1. Did the trial address a clearly focused issue? x   
2. Was the assignment of patients to treatments randomized? x   
3. Were all of the patients who entered the trial properly 
accounted for at its conclusion? 
x   
4. Were patients, health workers, and study personnel “blind” to 
treatment? 
x   
5. Were the groups similar at the start of the trial? x   
6. Aside from the experimental intervention, were the groups 
treated equally? 
x   
B) What are the results?  
7. How large was the treatment effect? 70 laparoscopic 
cholecystectomy 
patients. 
8. How precise was the estimate of the treatment effect? Decrease of myalgia 
was statistically 
significant. 
C) Will the results help locally?  
9. Can the results be applied in your context? (or to the local 
population) 
x   
10. Were all clinically important outcomes considered?   x 
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Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
 
Study 4:  Vyankatesh, J.S., Kiran, T.V., & Satish, D.G. (2016). Comparative study of 
pretreatment with rocuronium and vecuronium in post succinylcholine fasciculation, 
intubation condition and myalgia. Journal of Evolution of Medicine and Dental Sciences, 
5:38), 2319-2324. 
A) Are the results of the trial valid? Yes Can’t 
tell 
No 
1. Did the trial address a clearly focused issue? x   
2. Was the assignment of patients to treatments 
randomized? 
x   
3. Were all of the patients who entered the trial properly 
accounted for at its conclusion? 
x   
4. Were patients, health workers, and study personnel 
“blind” to treatment? 
x   
5. Were the groups similar at the start of the trial? x   
6. Aside from the experimental intervention, were the 
groups treated equally? 
x   
B) What are the results?  
7. How large was the treatment effect? 150 adult patients undergoing 
elective surgery. 
8. How precise was the estimate of the treatment effect? Both Rocuronium and 
Vecuronium were efficacious 
and the decrease in myalgia was 
statistically significant with 
both drugs. However, 
Rocuronium was noted to be 
more efficacious as compared 
to Vecuronium. 
C) Will the results help locally?  
9. Can the results be applied in your context? (or to the 
local population) 
x   
10. Were all clinically important outcomes considered? x   
11. Are the benefits worth the harms and costs? x   
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